Literature DB >> 28017326

The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation.

Vaibhav Keskar1, Eric McArthur2, Ron Wald3, Ziv Harel3, Deborah Zimmerman1, Amber O Molnar4, Amit X Garg5, Ngan N Lam6, Megan K McCallum7, Sarah E Bota2, Jeffrey Perl3, Manish M Sood8.   

Abstract

The utility of anticoagulants for ischemic stroke prophylaxis in elderly patients with chronic kidney disease (CKD) and atrial fibrillation remains uncertain. In this population-based retrospective cohort study, we determined the association of anticoagulant use with ischemic stroke or hemorrhage in elderly patients (66 years and older) with advanced chronic kidney disease (eGFR under 45 ml/min/1.73m2) and atrial fibrillation. We followed 6,544 patients with CKD and new onset atrial fibrillation, of whom 1,475 filled a prescription for an anticoagulant. We used propensity-score matched Cox proportional hazards and competing risk models to determine the time to first event of ischemic stroke, hemorrhage or mortality. After matching to examine exposure to anticoagulants, 1,417 matched pairs were identified. The crude rate of ischemic stroke and hemorrhage were 41.3 and 61.3 with anticoagulants and 34.4 and 34.3 without anticoagulants per 100 person-years, respectively. The hazard ratios of ischemic stroke, hemorrhage, and mortality for receipt of an anticoagulation prescription were 1.10 (95% confidence interval, 0.78-1.56), 1.42 (1.04-1.93), and 0.74 (0.62-0.88) as compared to non-receipt of anticoagulation. After accounting for the competing risk of death, the hazard ratios for ischemic stroke and hemorrhage were 1.12 (0.90-1.39) and 1.60 (1.31-1.97), respectively. The findings were consistent in a sensitivity analysis accounting for time varying anticoagulant exposure. Thus, in older patients with CKD and atrial fibrillation, receipt of an anticoagulant was not associated with a lower risk of ischemic stroke, but a higher risk of hemorrhage and a lower risk of mortality.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anticoagulation; atrial fibrillation; chronic kidney disease; elderly; hemorrhage; stroke

Mesh:

Substances:

Year:  2016        PMID: 28017326     DOI: 10.1016/j.kint.2016.10.017

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

1.  Vitamin K antagonists in the era of direct oral anticoagulants: is there still a room for their use?

Authors:  Francesco Dentali; Silvia Galliazzo; Francesca Zuretti; Monica Gianni
Journal:  Intern Emerg Med       Date:  2017-08-04       Impact factor: 3.397

2.  Anticoagulating atrial fibrillation patients: is there a kidney-friendly choice?

Authors:  Chun-Yih Hsieh
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 3.  Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.

Authors:  Tatjana S Potpara; Charles J Ferro; Gregory Y H Lip
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

Review 4.  Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.

Authors:  Savino Sciascia; Massimo Radin; Karen Schreiber; Roberta Fenoglio; Simone Baldovino; Dario Roccatello
Journal:  Intern Emerg Med       Date:  2017-09-19       Impact factor: 3.397

Review 5.  Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond: Medical and Ethical Issues.

Authors:  Tiberiu A Pana; Jesus A Perdomo-Lampignano; Phyo K Myint
Journal:  Curr Treat Options Neurol       Date:  2019-05-08       Impact factor: 3.598

Review 6.  Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz
Journal:  Toxins (Basel)       Date:  2018-06-12       Impact factor: 4.546

Review 7.  Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease.

Authors:  Katherine G Garlo; David J R Steele; Sagar U Nigwekar; Kevin E Chan
Journal:  Clin J Am Soc Nephrol       Date:  2018-12-28       Impact factor: 8.237

8.  Clinical Outcomes of Warfarin Initiation in Advanced Chronic Kidney Disease Patients With Incident Atrial Fibrillation.

Authors:  Manyoo A Agarwal; Praveen K Potukuchi; Keiichi Sumida; Adnan Naseer; Miklos Z Molnar; Lekha K George; Santhosh K Koshy; Elani Streja; Fridtjof Thomas; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  JACC Clin Electrophysiol       Date:  2020-09-16

9.  Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.

Authors:  Shinya Goto; Pantep Angchaisuksiri; Jean-Pierre Bassand; A John Camm; Helena Dominguez; Laura Illingworth; Harry Gibbs; Samuel Z Goldhaber; Shinichi Goto; Zhi-Cheng Jing; Sylvia Haas; Gloria Kayani; Yukihiro Koretsune; Toon Wei Lim; Seil Oh; Jitendra P S Sawhney; Alexander G G Turpie; Martin van Eickels; Freek W A Verheugt; Ajay K Kakkar
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

10.  Canadian Nephrologist Views Regarding Stroke and Systemic Embolism Prevention in Dialysis Patients With Nonvalvular Atrial Fibrillation: A Survey.

Authors:  David Collister; Jeff S Healey; David Conen; K Scott Brimble; Claudio Rigatto; Ziv Harel; Manish M Sood; Michael Walsh
Journal:  Can J Kidney Health Dis       Date:  2019-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.